149 related articles for article (PubMed ID: 28389458)
1. Probable interaction between levothyroxine and ritonavir: Case report and literature review.
Sahajpal R; Ahmed RA; Hughes CA; Foisy MM
Am J Health Syst Pharm; 2017 Apr; 74(8):587-592. PubMed ID: 28389458
[TBL] [Abstract][Full Text] [Related]
2. Early neuropsychological adverse events after switching from PI/r to dolutegravir could be related to hyperthyroidism in patients under levothyroxine.
Berger JL; Nguyen Y; Lebrun D; Migault C; Hentzien M; Marty H; Bani-Sadr F
Antivir Ther; 2017; 22(3):271-272. PubMed ID: 27834772
[TBL] [Abstract][Full Text] [Related]
3. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.
Touzot M; Beller CL; Touzot F; Louet AL; Piketty C
AIDS; 2006 May; 20(8):1210-2. PubMed ID: 16691080
[No Abstract] [Full Text] [Related]
4. Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.
Hills-Nieminen C; Hughes CA; Houston S; Shafran SD
Ann Pharmacother; 2009 Dec; 43(12):2117-20. PubMed ID: 19934385
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Crommentuyn KM; Mulder JW; Sparidans RW; Huitema AD; Schellens JH; Beijnen JH
Clin Infect Dis; 2004 Apr; 38(8):e73-5. PubMed ID: 15095234
[TBL] [Abstract][Full Text] [Related]
6. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
[TBL] [Abstract][Full Text] [Related]
8. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
9. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
[TBL] [Abstract][Full Text] [Related]
10. Interaction between levothyroxine and indinavir in a patient with HIV infection.
Lanzafame M; Trevenzoli M; Faggian F; Marcati P; Gatti F; Carolo G; Concia E
Infection; 2002 Jan; 30(1):54-5. PubMed ID: 11876520
[TBL] [Abstract][Full Text] [Related]
11. Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.
Sheehan NL; Brouillette MJ; Delisle MS; Allan J
Ann Pharmacother; 2006 Jan; 40(1):147-50. PubMed ID: 16368918
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Oldfield V; Plosker GL
Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
[TBL] [Abstract][Full Text] [Related]
14. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.
Koulouri O; Auldin MA; Agarwal R; Kieffer V; Robertson C; Falconer Smith J; Levy MJ; Howlett TA
Clin Endocrinol (Oxf); 2011 Jun; 74(6):744-9. PubMed ID: 21521256
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir.
Porche DJ
J Assoc Nurses AIDS Care; 2001; 12(2):101-4. PubMed ID: 11296724
[TBL] [Abstract][Full Text] [Related]
17. Hair loss induced by lopinavir-ritonavir.
Borrás-Blasco J; Belda A; Rosique-Robles D; Casterá E; Abad J; Amorós-Quiles I
Pharmacotherapy; 2007 Aug; 27(8):1215-8. PubMed ID: 17655521
[TBL] [Abstract][Full Text] [Related]
18. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
19. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.
Aung GL; O'Brien JG; Tien PG; Kawamoto LS
Ann Pharmacother; 2010 Nov; 44(11):1850-4. PubMed ID: 20978219
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir.
Hurst M; Faulds D
Drugs; 2000 Dec; 60(6):1371-9; discussion 1380-1. PubMed ID: 11152017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
